Affordable Access

deepdyve-link
Publisher Website

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Authors
  • Nelson, M R
  • Elion, R A
  • Cohen, C J
  • Mills, A
  • Hodder, S L
  • Segal-Maurer, S
  • Bloch, M
  • Garner, W
  • Guyer, B
  • Williams, S
  • Chuck, S
  • Vanveggel, S
  • Deckx, H
  • Stevens, M
Type
Published Article
Journal
HIV clinical trials
Publication Date
Jan 01, 2013
Volume
14
Issue
3
Pages
81–91
Identifiers
DOI: 10.1310/hct1403-81
PMID: 23835510
Source
Medline
License
Unknown

Abstract

The pooled ECHO and THRIVE studies demonstrated noninferiority of RPV+FTC/TDF in achieving virologic response with safety and tolerability advantages over EFV+FTC/TDF through 96 weeks. Higher rates of virologic failure in the RPV+FTC/TDF group were balanced with higher rates of discontinuations due to adverse events in the EFV+FTC/TDF group.

Report this publication

Statistics

Seen <100 times